Abstract
Background. In order to determine whether recombinant human erythropoietin (rHuEPO) may play a role in treating anemia in idiopathic myelofibrosis (IMF), a pilot study using high doses of rHuEPO was conducted on patients with IMF. Methods and results. From September, 1990 to December, 1992, 7 patients (6 males and 1 female, median age 68 years) affected by IMF entered the trial. RHuEPO was administered subcutaneously 5 days a week at a dosage of 160 U/kg daily for three mouths. Out of 7 patients, 4 obtained a response. These responders received additional maintenance treatment with rHuEPO until relapse. Response duration was 6, 7, 10+, and 16 months, respectively. Treatment was well-tolerated. Conclusions. Our data suggest that rHuEPO may play a role in the treatment of anemia in some IMF patients.
| Original language | English |
|---|---|
| Pages (from-to) | 371-373 |
| Number of pages | 3 |
| Journal | Haematologica |
| Volume | 78 |
| Issue number | 6 |
| Publication status | Published - 1993 |
Fingerprint
Keywords
- erythropoietin
- idiopathic myelofibrosis
ASJC Scopus subject areas
- Hematology
Cite this
Erythropoietin treatment of idiopathic myelofibrosis. / Aloe Spiriti, M. A.; Latagliata, R.; Avvisati, G.; Battistel, V.; Montefusco, E.; Spadea, A.; Petti, M. C.
In: Haematologica, Vol. 78, No. 6, 1993, p. 371-373.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Erythropoietin treatment of idiopathic myelofibrosis
AU - Aloe Spiriti, M. A.
AU - Latagliata, R.
AU - Avvisati, G.
AU - Battistel, V.
AU - Montefusco, E.
AU - Spadea, A.
AU - Petti, M. C.
PY - 1993
Y1 - 1993
N2 - Background. In order to determine whether recombinant human erythropoietin (rHuEPO) may play a role in treating anemia in idiopathic myelofibrosis (IMF), a pilot study using high doses of rHuEPO was conducted on patients with IMF. Methods and results. From September, 1990 to December, 1992, 7 patients (6 males and 1 female, median age 68 years) affected by IMF entered the trial. RHuEPO was administered subcutaneously 5 days a week at a dosage of 160 U/kg daily for three mouths. Out of 7 patients, 4 obtained a response. These responders received additional maintenance treatment with rHuEPO until relapse. Response duration was 6, 7, 10+, and 16 months, respectively. Treatment was well-tolerated. Conclusions. Our data suggest that rHuEPO may play a role in the treatment of anemia in some IMF patients.
AB - Background. In order to determine whether recombinant human erythropoietin (rHuEPO) may play a role in treating anemia in idiopathic myelofibrosis (IMF), a pilot study using high doses of rHuEPO was conducted on patients with IMF. Methods and results. From September, 1990 to December, 1992, 7 patients (6 males and 1 female, median age 68 years) affected by IMF entered the trial. RHuEPO was administered subcutaneously 5 days a week at a dosage of 160 U/kg daily for three mouths. Out of 7 patients, 4 obtained a response. These responders received additional maintenance treatment with rHuEPO until relapse. Response duration was 6, 7, 10+, and 16 months, respectively. Treatment was well-tolerated. Conclusions. Our data suggest that rHuEPO may play a role in the treatment of anemia in some IMF patients.
KW - erythropoietin
KW - idiopathic myelofibrosis
UR - http://www.scopus.com/inward/record.url?scp=0027851312&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027851312&partnerID=8YFLogxK
M3 - Article
VL - 78
SP - 371
EP - 373
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 6
ER -